reported higher response rates to immune checkpoint inhibitors and significantly prolonged overall survival in renal cell carcinoma patients with PBRM1 mutations, suggesting PBRM1 as a predictive marker for immunotherapy efficacy (16). The gene discussed is PBRM1; the disease is hereditary clear cell renal cell carcinoma.